Protein kinase C
hideProtein kinase C also known as PKC (EC 2.7.11.13) is a family of enzymes that are involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins. PKC enzymes in turn are activated by signals such as increases in the concentration of diacylglycerol. Hence PKC enzymes play important roles in several signal transduction cascades.
The PKC family consists of ~10 isozymes. They are divided into three subfamilies, based on their second messenger requirements: conventional (or classical), novel, and atypical. Conventional (c)PKCs contain the isoforms α, βI, βII, and γ. These require Ca2+, diacylglycerol (DAG), and a phospholipid such as phosphatidylserine for activation. Novel (n)PKCs include the δ, ε, η, and θ isoforms, and require DAG, but do not require Ca2+ for activation. Thus, conventional and novel PKCs are activated through the same signal transduction pathway as phospholipase C. On the other hand, atypical (a)PKCs (including protein kinase Mζ and ι / λ isoforms) require neither Ca2+ nor diacylglycerol for activation. The term "protein kinase C" usually refers to the entire family of isoforms.
For more information about Protein kinase C, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with protein kinase c
New findings bring hope for possible Parkinson's disease cure
Nov 03, 2009 |
5 / 5 (4) |
0
Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others.
Why one way of learning is better than another
Medicine & Health / Neuroscience
Oct 01, 2009 |
4 / 5 (3) |
0
A new study from the Montreal Neurological Institute and Hospital (The Neuro) of McGill University reveals that different patterns of training and learning lead to different types of memory formation. The significance of ...
2-drug combination appears safe and active in metastatic kidney cancer
May 31, 2009 |
1 / 5 (1) |
0
Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may ...
How an enzyme tells stem cells which way to divide
May 14, 2009 |
5 / 5 (4) |
0
Driving Miranda, a protein in fruit flies crucial to switch a stem cell's fate, is not as complex as biologists thought, according to University of Oregon biochemists. They've found that one enzyme (aPKC) ...
Researchers uncover 'obesity gene' involved in weight gain response to high-fat diet
Feb 24, 2009 |
5 / 5 (1) |
3
Scientists have determined that a specific gene plays a role in the weight-gain response to a high-fat diet. The finding in an animal study suggests that blocking this gene could one day be a therapeutic strategy to reduce ...
Cell biologists identify new tumor suppressor for lung cancer
Jan 05, 2009 |
not rated yet |
0
Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help scientists develop more targeted drug therapies to combat lung cancer.
